Linefor (Pregabalin)

Pregabalin binds to the α2‑δ subunit of voltage‑gated calcium channels in the central nervous system. This reduces calcium entry into nerve terminals, decreasing the release of excitatory neurotransmitters such as glutamate, norepinephrine and substance P, thereby dampening neuronal hyperexcitability.

The appropriate dose of Linefor is individualized by the prescribing healthcare professional based on the specific indication, patient age, renal function, and response to therapy. Dosage adjustments may be required for certain populations, and patients should follow the prescriber’s instructions exactly.

Safety of pregabalin in pregnancy and lactation has not been firmly established. It is classified as a category C medication in many regions, meaning potential risks exist. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential benefits and risks with their healthcare provider.

To order Linefor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to pregabalin is gabapentin, another gabapentinoid. Both share a similar mechanism of binding to the α2‑δ calcium‑channel subunit, but pregabalin generally has higher potency, more predictable pharmacokinetics, and may require fewer daily doses compared with gabapentin.

Linefor should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct light, and ensure they are out of reach of children.

Linefor is taken orally, usually with or without food. Tablets should be swallowed whole with a glass of water and not chewed, crushed, or split unless specifically instructed by a healthcare professional.

Serious risks include angioedema (swelling of the face, lips, tongue or throat), severe skin reactions such as Stevens‑Johnson syndrome, and emergence of suicidal thoughts or behaviors. Patients should seek immediate medical attention if they notice any of these symptoms.

Linefor is contraindicated in patients with known hypersensitivity to pregabalin or any of its excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled heart failure, or those taking interacting CNS depressants without close monitoring.